4444/A23

Sulindac Confers Protection Against Oxidative Stress Induced Damage In Retinal Pigment Epithelial Cells



Purpose – The retinal pigment epithelial (RPE) layer is one of the major areas affected by oxidative stress in ocular diseases. In our study we tested the non-steroidal anti-inflammatory compound (NSAID) sulindac

for protection against oxidative stress induced damage in RPE cells. Besides its known anti-inflammatory activity, recent studies have shown that sulindac can protect cardiac cells against oxidative damage by a preconditioning mechanism. Methods - The ability of sulindac to protect RPE cells against oxidative stress was determined by treating cultured RPE cells with sulindac, before exposing them to oxidative stress. Following 48h exposure of RPE cells to sulindac, cells were exposed to either a range of *tert*-Butyl Hydrogen peroxide (t-BHP) concentrations or Hydrogen peroxide (H2O2) to induce oxidative stress. For inducing Hypoxia, RPE cells were exposed to less than 0.5% oxygen environment in a hypoxia chamber. After the treatments cellular viability was determined using the MTT assay. Results- The results show that exposure of cultured RPE cells to oxidative stress using t-BHP or H2O2 or Hypoxia causes significant

decrease in cell viability. Pretreatment of RPE cells with sulindac for 48hrs, protects them against these insults and enhances survival.

Conclusion- In future experiments we plan on showing that the mechanism of protection, and also test whether, sulindac is functioning as a preconditioning agent. To understand this protective mechanism we will evaluate changes in preconditioning markers, role of ROS scavengers and mitochondrial function. In our future studies we plan on investigating the efficacy of combining sulindac in a dual therapy along with the reducing agent methionine sulfoxide reductase A (MsrA). We will also furhter extend our investigation to animal model of photooxidation where mice will be treated with UV light and the ability of sulindac to prevent UV induced damage will be evaluated. In conclusion we believe that sulindac may represent a novel therapeutic agent for oxidative stress induced ocular diseases.

Methods

For protecting RPE cells from oxidative stress induced damage we used the NSAID, sulindac. For our experiment we used ARPE-19 cells cultured in 96 well plates. The cells were preincubated with sulindac for 48 hours prior to exposing them to oxidative stress. Our oxidizing agents of choice were TBHP and Hydrogen peroxide (H_2O_2) . We also stressed the ARPE-19 cells with 24 hours of Hypoxia treatment. After the stress the cellular viability was evaluated using the MTS assay. This assay uses a tetrazolium compound that is bioreduced into a formazan product in the cells. The signal generated (color intensity) is directly proportional to the number of viable (metabolically active) cells in the wells.






Figure 1: Structure of sulindac and its analogues. Sulindac can be reduced to an active NSAID sulfide form or irreversibly oxidized to a sulfone analogue. The sulfoxide form of sulindac retains the functions of NSAID through COX inhibitory properties

Arunodoy Sur^a, Manas Biswal^a, Alexander Kreymerman^b, Herbert Weissbach^b, Howard Prentice^a and Janet Blanks^a ^aDepartment of Biology, Boca Raton, FL and ^b Center for Molecular Biology and Biotechnology; Florida Atlantic University; Jupiter, FL


Results











Results